Non-alcoholic fatty liver disease: What the clinician needs to know
Open Access
- 1 January 2014
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (36), 12956-80
- https://doi.org/10.3748/wjg.v20.i36.12956
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of liver disease in the Western world. Furthermore, it is increasing worldwide, paralleling the obesity pandemic. Though highly frequent, only about one fifth of affected subjects are at risk of developing the progressive form of the disease, non-alcoholic steatohepatitis with fibrosis. Even in the latter, liver disease is slowly progressive, though, since it is so prevalent, it is already the third cause of liver transplantation in the United States, and it is predicted to get to the top of the ranking in few years. Of relevance, fatty liver is also associated with increased overall mortality and particularly increased cardiovascular mortality. The literature and amount of published papers on NAFLD is increasing as fast as its prevalence, which makes it difficult to keep updated in this topic. This review aims to summarize the latest knowledge on NAFLD, in order to help clinicians understanding its pathogenesis and advances on diagnosis and treatment.Keywords
This publication has 183 references indexed in Scilit:
- Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver diseaseHepatology, 2011
- Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trialHepatology, 2011
- Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitisHepatology, 2010
- PNPLA3variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic diseaseHepatology, 2010
- The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver diseaseHepatology, 2010
- High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trialHepatology, 2010
- Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver diseaseHepatology, 2010
- Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitisHepatology, 2009
- The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLDHepatology, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseHepatology, 2005